Since President Donald J. Trump took office a second time on Jan. 20, leaders across the biotechnology and pharmaceutical ...

President Donald Trump’s plan to change the pricing model for some medications is facing fierce criticism from the ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

The pharma industry in India continues to grow rapidly and as it does the regulatory environment continues to shift. With over thirty years experience in pharma Tapan Ray has a broad overview of ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of ...

Would the Trump administration's recently proposed drug pricing reforms hurt the biotech sector more than pharma? Seeking ...

While the Trump administration has painted the jettisoning of staff and regulations as good for business, there are multiple ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

about the impact geopolitical changes in Europe might have on the bio/pharmaceutical industry. Political shifts in the United Kingdom and Europe may have a negative impact on research efforts for gene ...